Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy
Oral tyrosine kinase inhibitors (TKIs) against epidermal growth factor receptor (EGFR) family have been introduced into the clinic to treat human malignancies for decades. Despite superior properties of EGFR-TKIs as small molecule targeted drugs, their applications are still restricted due to their...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-01-01
|
| Series: | Asian Journal of Pharmaceutical Sciences |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1818087619303939 |